Edgewise Therapeutics Inc (EWTX) Quote

Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target

I'm surprised stock didn't do better on recent P 2 data ...which was supposed to " de risk " their program

Kiwi

BOULDER, Colo., February 13, 2024--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
EDG-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne and Becker muscular dystrophy (Becker).
The FDA previously granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne and Becker, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designation for the treatment of Becker.
---------------
Kiwi

RMB. for what its worth ...both stocks I mentioned are now "technically " over bought ...so some pull back near term is likely
jmo
Kiwi

RMB. EWTX up 21 % in past week. ( since your post )
VERA ,,,which I think U saw me posting on at the AUPH board ...up 28%
Both I think at 52 wk highs

Usually I find it best to initiate small positions ...follow ..and then if the data still looks good , add on a pullback due to some unrelated event .
Both of these Co's have a lot of data coming out in 2024

Kiwi

EWTX new 52 week high

EWTX new 52 week high

Jonathan C. Fox, M.D., Ph.D., FACC
DIRECTOR
Jonathan C. Fox, M.D., Ph.D., FACC, serves as a member of our board of directors and is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, Dr. Fox served as the chief medical officer of MyoKardia, Inc. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, and held various senior R&D positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca. He was also on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research. He is currently an adjunct Professor of Medicine at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.


MyoKardia was bt out by BMS
Kiwi

RMB. You might look at TNYA also ...similar space. Ceo is one very smart guy and is backed by the Column group ( smart team )
Early days tho .
EWTX is far further along

BOTH are high speculative ...so.....etc
Kiwi

Kiwi you have peaked my interest in EWTX

The opportunity seems to be here, but I will try to exhibit something I rarely do, namely; patience.

It has risen a bunch in a short time and I hope to pick some up after a bit of a retracement.

EWTX. Best Co I've seen in this area since MYOK ...which was eventually bt out .
Kiwi

Impressive presentation at JPM 2024 . Fast tracked but the earliest they are likely to have an approved drug is early 2026...if all goes well
Kiwi

Looks like we may have hit the bottom lol

Jumped in at $30 today hope we have a good run here

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) gained 87.5% to close at $30.00 after pricing its IPO at $16 per share.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The Company is principally focused on discovering, developing and commercializing treatments for rare muscle disorders. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The Company's lead candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The Company's research programs include EDG-6289, EDG-002 and EDG-003.